Nutra Pharma Letter to Shareholders www.nutrapha
Post# of 102
(Total Views: 819)
Posted On: 01/16/2018 1:35:05 PM
Nutra Pharma Letter to Shareholders
www.nutrapharma.com/Dec2017_shareholder_letter.pdf
Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company
CORAL SPRINGS, Fla., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
“This has been a very busy year at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “2017 provided some real challenges and opportunities for the Company. This has provided a strong platform for real growth in 2018," he continued. "I wanted to take this opportunity to update our shareholders and the public on the accomplishments of the year, the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.
The letter includes some of the following accomplishments made by the Company over the past year:
We were featured in television news segments that ran nationally on NBC news from the NBC-Miami station and internationally on the Spanish language show, Primero Impacto.
We announced a collaboration with the International Security Group to investigate the use of our technology as a counter measure against nerve agents.
We announced a collaboration with the University Of Maryland Bioprocess Scale-Up Facility (BSF) to optimize manufacturing processes for the production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis.
We launched Luxury Feet, a new version and packaging of our OTC pain drug, Nyloxin, specifically marketed for the treatment and prevention of pain and discomfort that women experience from wearing high heels.
We announced that the textbook, Multimodal Management of Canine Osteoarthritis, Second Edition, includes references to Nutra Pharma's development of cobra venom-based products for treating pain in dogs; directly supporting Pet Pain-Away.
www.nutrapharma.com/Dec2017_shareholder_letter.pdf
Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company
CORAL SPRINGS, Fla., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
“This has been a very busy year at Nutra Pharma,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “2017 provided some real challenges and opportunities for the Company. This has provided a strong platform for real growth in 2018," he continued. "I wanted to take this opportunity to update our shareholders and the public on the accomplishments of the year, the status of the Company and briefly outline our goals and expectations for the coming months,” he concluded.
The letter includes some of the following accomplishments made by the Company over the past year:
We were featured in television news segments that ran nationally on NBC news from the NBC-Miami station and internationally on the Spanish language show, Primero Impacto.
We announced a collaboration with the International Security Group to investigate the use of our technology as a counter measure against nerve agents.
We announced a collaboration with the University Of Maryland Bioprocess Scale-Up Facility (BSF) to optimize manufacturing processes for the production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis.
We launched Luxury Feet, a new version and packaging of our OTC pain drug, Nyloxin, specifically marketed for the treatment and prevention of pain and discomfort that women experience from wearing high heels.
We announced that the textbook, Multimodal Management of Canine Osteoarthritis, Second Edition, includes references to Nutra Pharma's development of cobra venom-based products for treating pain in dogs; directly supporting Pet Pain-Away.
(0)
(0)